A phase III study of IDO inhibitors with ICIs in unresectable melanoma has been reported; however, IDO inhibitors plus PD‐1 inhibitors do not improve patient outcomes relative to the placebo plus PD‐1 inhibitors.33 Here, IDO1 is linked to melanoma.